Fmoc-Phe-Lys(Boc)-PAB-PNP is a protected dipeptide ADC linker with a PNP leaving group for efficient payload conjugation. Featuring a self-immolative PAB unit, it ensures controlled drug release, supporting versatile bioconjugation strategies in targeted therapeutics.
Structure of 1646299-50-4
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Fmoc-Phe-Lys(Boc)-PAB-PNP is a chemical reagent used in peptide synthesis and related research. Here are some key applications of Fmoc-Phe-Lys(Boc)-PAB-PNP:
Peptide Synthesis: Fmoc-Phe-Lys(Boc)-PAB-PNP is commonly used in solid-phase peptide synthesis (SPPS) as a building block for the creation of peptides. It enables the incorporation of protected amino acids, facilitating the stepwise assembly of complex peptide sequences. This reagent ensures high yield and purity in the synthesized peptides, which are critical for research and therapeutic applications.
Proteomics Research: In proteomics, Fmoc-Phe-Lys(Boc)-PAB-PNP is employed to construct synthetic peptide libraries for screening and analyzing protein interactions. These libraries can help identify binding motifs and functional domains within proteins. Researchers use these insights to understand protein functions and develop inhibitors or modulators for therapeutic purposes.
Drug Discovery: Fmoc-Phe-Lys(Boc)-PAB-PNP aids in the development of peptidomimetics and peptide-based drugs by allowing precise modification and conjugation of peptides. Researchers can design peptides with improved stability, bioavailability, and specificity for target proteins. This application is vital in creating new therapeutic agents for diseases like cancer and infectious diseases.
Immunology Studies: In immunological research, Fmoc-Phe-Lys(Boc)-PAB-PNP is used to synthesize peptide antigens for the development of vaccines and diagnostic assays. Synthetic peptides can effectively mimic pathogen-derived antigens, eliciting specific immune responses when introduced into the body. This approach is essential for creating targeted vaccines and improving diagnostic accuracy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00709 | Fmoc-Phe-Lys(Trt)-PAB | 1116085-98-3 | |
BADC-00495 | Fmoc-Phe-Lys(Trt)-PAB-PNP | 1116086-09-9 |
What is Fmoc-Phe-Lys(Boc)-PAB-PNP and its role in ADC linkers?
Fmoc-Phe-Lys(Boc)-PAB-PNP is a dipeptide-based self-immolative linker. The Fmoc and Boc groups protect amino functionalities during synthesis, and the PAB-PNP moiety enables selective payload release after enzymatic cleavage, providing controlled intracellular delivery in ADCs.
19/8/2021
We would like to know how Fmoc-Phe-Lys(Boc)-PAB-PNP facilitates payload release.
The peptide sequence is recognized by intracellular proteases. Cleavage triggers self-immolation of the PAB moiety, releasing the payload in its active form, while the linker remains stable in circulation before reaching the target cells.
25/10/2017
Could you advise which payloads are suitable for Fmoc-Phe-Lys(Boc)-PAB-PNP?
It can be conjugated to amine-containing cytotoxins, fluorescent probes, or peptides. The design ensures selective release while maintaining solubility and stability of the resulting ADC complex.
12/2/2022
Could you please advise the recommended synthesis conditions for this linker?
Fmoc-Phe-Lys(Boc)-PAB-PNP is synthesized using standard solid-phase peptide synthesis. Deprotection is performed under mild basic conditions before coupling to antibodies or payloads for ADC formation.
23/12/2018
Good morning! What are the typical specifications and handling precautions for Fmoc-Phe-Lys(Boc)-PAB-PNP?
Fmoc-Phe-Lys(Boc)-PAB-PNP is supplied with detailed specifications covering molecular weight, solubility profile, and functional group characterization. Handling precautions include using gloves and protective equipment, storing under inert atmosphere at low temperature, and avoiding prolonged exposure to moisture or light. Refer to the product datasheet for detailed safety guidelines.
23/9/2017
— Dr. Jonathan White, Medicinal Chemist (UK)
Fmoc-Phe-Lys(Boc)-PAB-PNP demonstrated high coupling efficiency and excellent purity for our ADC studies.
12/2/2022
— Ms. Clara Hoffmann, Biochemist (Germany)
Batch-to-batch reproducibility of Fmoc-Phe-Lys(Boc)-PAB-PNP was outstanding.
23/9/2017
— Dr. William Parker, Senior Scientist (USA)
We achieved efficient conjugation with minimal optimization using Fmoc-Phe-Lys(Boc)-PAB-PNP.
23/12/2018
— Dr. Elise Moreau, Chemist (France)
The solubility and stability of Fmoc-Phe-Lys(Boc)-PAB-PNP simplified multi-step linker synthesis.
19/8/2021
— Mr. Noah Brown, Bioconjugation Specialist (Canada)
QC and documentation were thorough, supporting regulatory submissions.
— Ms. Isabella Rossi, Medicinal Chemist (Italy)
Fmoc-Phe-Lys(Boc)-PAB-PNP was instrumental in our solid-phase synthesis, providing clean coupling and minimal by-products. BOC Sciences support team was very responsive.
25/10/2017
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.